What is the first‑line regimen for uncomplicated brucellosis, and is linezolid an appropriate alternative to streptomycin?

First-Line Treatment for Uncomplicated Brucellosis

Doxycycline 100 mg twice daily for 6 weeks combined with streptomycin 15 mg/kg intramuscularly daily for 2–3 weeks is the first-line regimen for uncomplicated brucellosis, achieving the lowest relapse rate of approximately 5%. 1, 2

Primary Treatment Recommendation (AI – Highest Evidence)

The doxycycline-streptomycin combination is superior to all alternatives and should be your default choice when streptomycin is available and intramuscular administration is feasible. 3, 1 This regimen consistently demonstrates:

• Relapse rates of only 5% compared to 16% with doxycycline-rifampicin 1, 2
• Significantly better efficacy with an odds ratio of 3.17 (95% CI 2.05-4.91) favoring doxycycline-streptomycin over doxycycline-rifampicin 4, 2
• AI recommendation status (highest quality evidence from randomized controlled trials) 3, 1

Is Linezolid an Appropriate Alternative to Streptomycin?

No, linezolid is not mentioned in any brucellosis treatment guidelines and should not be used as an alternative to streptomycin. 3, 1, 5 The evidence-based alternatives to streptomycin are:

Gentamicin (BI Recommendation – Preferred Alternative)

Gentamicin 5 mg/kg parenterally once daily for 7 days combined with doxycycline is the appropriate aminoglycoside alternative when streptomycin is unavailable. 3, 1

• Offers comparable efficacy to streptomycin with relapse rates of 10–20% 1
• Has wider availability than streptomycin 3
• Carries a BI recommendation (moderate evidence, generally recommended) 3, 1
• No significant difference in outcomes compared to doxycycline-streptomycin (OR 1.89,95% CI 0.81-4.39) 4

Rifampicin (AI Recommendation – Oral Alternative)

Doxycycline-rifampicin (600–900 mg daily for 6 weeks) is an AI-recommended alternative only when intramuscular therapy is impractical or aminoglycosides are contraindicated. 3, 1

However, this regimen has critical disadvantages:

• Three-fold higher relapse rate (16% vs 5%) compared to doxycycline-streptomycin 1, 2
• Risk of promoting mycobacterial resistance in regions where tuberculosis is endemic 1, 5
• Should be considered second-choice despite its AI recommendation 5

Treatment Algorithm

Use this decision tree:

1. Can the patient receive intramuscular injections AND is streptomycin available?

   • Yes → Doxycycline + streptomycin (15 mg/kg IM daily × 2–3 weeks) 3, 1
   • No → Proceed to step 2

2. Is gentamicin available?

   • Yes → Doxycycline + gentamicin (5 mg/kg IV/IM daily × 7 days) 3, 1
   • No → Proceed to step 3

3. Is tuberculosis endemic in your region?

   • No → Doxycycline + rifampicin (600–900 mg daily × 6 weeks) 3, 1
   • Yes → Avoid rifampicin; consider doxycycline + trimethoprim-sulfamethoxazole (CII recommendation, higher relapse risk) 3, 1

Critical Treatment Principles

Duration is Non-Negotiable

• All regimens require 6 weeks of doxycycline 3, 1, 6
• Courses shorter than 4 weeks result in unacceptably high relapse rates of 22% 1
• Do not extend to 8 weeks for uncomplicated disease—a randomized trial found no benefit (9.7% vs 13.9% relapse, p = NS) 6

Combination Therapy is Mandatory

• Monotherapy yields 13% relapse rates versus 4.8% with combination therapy 1, 7
• Never use doxycycline alone, even though one well-designed trial suggested comparable efficacy 3

Aminoglycoside Dosing Must Be Adequate

• Streptomycin requires 14–21 days (not 7 days) to achieve optimal outcomes 1
• Gentamicin requires 7 days minimum 3, 1
• Do not use fixed 500 mg gentamicin dosing—always calculate 5 mg/kg 1

Common Pitfalls to Avoid

• Do not choose rifampicin-based regimens first-line when streptomycin or gentamicin are available—the relapse rate is 3× higher 1, 2
• Do not shorten aminoglycoside courses below recommended durations (streptomycin 14 days, gentamicin 7 days) 1
• Do not discontinue therapy early based on symptom resolution—microbiological cure lags behind clinical improvement 1
• Do not use trimethoprim-sulfamethoxazole as monotherapy—relapse rates reach 46% 3, 1
• Do not use quinolones (ciprofloxacin, ofloxacin) as first-line agents—they carry CII recommendations and should be reserved for second- or third-line use 3, 1, 8

Expected Outcomes

• Even with optimal therapy, expect 5–15% relapse rates 1, 5
• Relapses are usually mild and respond to the same regimen 1
• Symptom resolution typically occurs within 9.5 days, but complete the full 6-week course 6